Gulam Manji
Columbia University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gulam Manji as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06048484 · Combination Therapy in Patients With Localized Pancreatic Ductal AdenocarcinomaGulam Manji · recruiting · Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph2NCT04543071 · Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic AdenocarcinomaColumbia University · active not recruiting · Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma · principal investigator
- N/ANCT04476537 · RNA Precision Oncology in Advanced Pancreatic CancerColumbia University · terminated · Pancreatic Cancer · principal investigator
- Ph1/Ph2NCT04214418 · Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced MalignanciesColumbia University · terminated · Gastrointestinal Cancer · principal investigator
- Ph2NCT03979066 · Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal AdenocarcinomaGulam Manji · terminated · Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph2NCT02918162 · Perioperative Chemo and Pembrolizumab in Gastric CancerGulam Manji · completed · Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Elucidation and targeting of paracrine cascades in PDACU01CA274312 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2022 to 2026 · $985,518 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancerR01CA266558 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2023 to 2026 · $593,512 awarded in 2026Same name and institution; not confirmed by an ID
- Phase 2 study of combination therapy with PLX3397 and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumorsR01FD005745 · FDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2017 to 2023 · $405,830 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:53 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- 82 citationsRCR 41.0
- 68 citationsRCR 6.8
- 59 citationsRCR 4.7
- Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.Clin Cancer Res · 202048 citationsRCR 2.0
- Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.JAMA Oncol · 202322 citationsRCR 1.4
- Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.Oncologist · 202513 citationsRCR 2.9
- 10 citationsRCR 5.0
- A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery.Oncologist · 20254 citationsRCR 0.8